Jakafi

Doses may be given by NG tube if unable to swallow tabs. MF: Platelets >200×10⁹/L: initially 20mg twice daily. Platelets 100–200×10⁹/L: initially 15mg twice daily. Platelets 50–<100×10⁹/L: initially 5mg twice daily. May increase doses by 5mg twice daily to a max of 25mg twice daily; do not increase during the first 4 weeks of therapy and not more frequently than every 2 weeks. Discontinue treatment after 6 months if no reduction in spleen size or symptom improvement. Interrupt treatment if platelets <50×10⁹/L or ANC <0.5×10⁹/L. May restart after recovery of platelets or ANC (see full labeling for max allowable restarting doses). Consider dose reductions if platelets decrease but remain ≥50×10⁹/L (see full labeling). Dose modifications for patients starting treatment with platelets 50–<100×10⁹/L: see full labeling. PV: initially 10mg twice daily. May increase doses by 5mg twice daily to a max of 25mg twice daily; do not increase during the first 4 weeks of therapy and not more frequently than every 2 weeks. Consider dose reductions for Hgb and/or platelet decreases (see full labeling). Interrupt treatment if Hgb <8g/dL, platelets <50×10⁹/L, or ANC <1.0×10⁹/L. May restart after recovery of hematologic parameters (see full labeling for max allowable restarting doses). Concomitant strong CYP3A4 inhibitors or fluconazole ≤200mg (MF): initially 10mg twice daily if platelets ≥100×10⁹/L; if platelets 50–<100×10⁹/L: initially 5mg once daily; (PV): initially 5mg twice daily. Other reductions, hepatic or renal impairment, ESRD: see full labeling.